ORLANDO — In this video from the American Academy of Ophthalmology meeting, David A. Eichenbaum, MD, FASRS, discusses how geographic atrophy remains the most significant unmet need in retina.
“We would like therapies that do more, and the good news is we have a robust pipeline of early-stage assets that have a lot of promise,” Eichenbaum, of Retina Vitreous Associates of Florida, told Healio.
Three-year results of the GATHER2 open-label extension trial evaluating Izervay (avacincaptad pegol intravitreal solution, Astellas) were presented at the meeting, demonstrating that